- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03937843
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma. A Multicenter, Open Label Phase II Trial With Two Cohorts
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Therapy de-escalation in stage IIA/B seminoma represents an unmet need in clinical practice; efficacy of modern standard of care therapies for these patients is high and only a few patients show disease recurrence but short- and long-term toxicities are a major concern. The magnitude of long-term toxicities is often associated with the intensity of the prescribed treatment modality. A higher cumulative dose of chemotherapy agents and radiation dose has been linked to a sharp increase in long-term sequelae. Combining treatment modalities and diversifying toxicity may thus provide an opportunity to limit long-term treatment sequelae.
In this trial carboplatin, cisplatin and etoposide are the Investigational Medicine Products (IMPs). They are all medications with a marketing authorization for several solid tumor types and are standard practice in the treatment of testicular cancer in Switzerland and in the European Union (EU).
Radiotherapy is also a standard therapy in this indication.
However, the trial investigates a stage-adapted (stage IIA or IIB) de-escalation of these standard treatments in the context of a multimodality treatment with chemo- and radiotherapy. The goal is to safely de-escalate treatment while maintaining/enhancing efficacy, which is not a standard practice yet.
The SAKK 01/18 trial is designed with the aim to answer these three questions:
- Can the dose of involved-node radiotherapy be safely reduced in the context of multimodality treatment with chemo- and radiotherapy?
- Can a more potent chemotherapy in the form of cisplatin/etoposide reduce the rate of distant failure in comparison to carboplatin?
- Can a combination of cisplatin/etoposide and involved-node radiotherapy pose a potent treatment regime for patients with recurrence after adjuvant carboplatin or radiotherapy for stage I seminoma? Furthermore, as active surveillance is becoming standard of care in stage I seminoma, it is projected that the amount of patients in need of treatment with stage IIA/B disease will rise, due to more patients developing disease progression during active surveillance.
The trial design, trial treatment and trial specifics are a consensus among the Swiss Urogenital Tumors Project Group and the Swiss Radio-oncology Section from the Swiss Group for Clinical Cancer Research (SAKK) and the German Testicular Cancer Study Group (GTCSG).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Corinne Schär, PhD
- Phone Number: +41 31 389 91 91
- Email: trials@sakk.ch
Study Locations
-
-
-
Berlin, Germany, 13125
- HELIOS Klinikum Berlin-Buch
-
Berlin, Germany, 10967
- Vivantes Klinikum Am Urban
-
Essen, Germany, 45136
- Evang. Kliniken Essen-Mitte
-
Hamburg, Germany, 20246
- Universitätsklinikum Hamburg-Eppendorf
-
Hamburg, Germany, 22763
- Asklepios Kliniken
-
Ludwigsburg, Germany, 71640
- RKH Klinikum Ludwigsburg
-
München, Germany, 80364
- Rotkreuzklinikum Munchen
-
Tübingen, Germany, 72076
- Universitatsklinikum Tubingen
-
Ulm, Germany, 89075
- Universitatsklinikum Ulm
-
-
-
-
-
Basel, Switzerland, CH-4031
- Universitaetsspital-Basel
-
Bellinzona, Switzerland, CH-6500
- Istituto Oncologico della Svizzera Italiana (IOSI)
-
Bern, Switzerland, 3010
- Inselspital Bern
-
Chur, Switzerland, 7000
- Kantonsspital Graubuenden
-
Chur, Switzerland, 7000
- Kantonsspital Graubünden
-
Lausanne, Switzerland, CH-1011
- Centre hospitalier universitaire vaudois CHUV
-
Sion, Switzerland, 1951
- Hopital de Sion
-
St. Gallen, Switzerland, CH-9007
- Kantonsspital - St. Gallen
-
Winterthur, Switzerland, 8401
- Kantonsspital Winterthur
-
Zürich, Switzerland, 8091
- Universitätsspital Zürich
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent according to ICH/GCP (International Council on Harmonization/Good Clinical Practice) regulations before registration and prior to any trial specific procedures
- Histologically confirmed classical seminoma treated with primary inguinal orchidectomy or partial orchidectomy
- Patients with a seminoma stage IIA or IIB, either newly diagnosed or recurrent after primary active surveillance, adjuvant carboplatin or radiotherapy for stage I disease. The tumor stage is pT1-4 cN1-2 cM0 according to UICC TNM 8th edition 2016. Patients with a recurrent seminoma stage IIA or IIB are only eligible in case of progression under active surveillance or recurrence after adjuvant carboplatin or radiotherapy for stage I disease
- Stage IIA, in patients with equivocal lymph node enlargement, needs to be confirmed with a repeated CT/MRI scan of the abdomen (suggested timeframe: 4 weeks after the previous scan) in order to rule out false positive lymph node enlargement.
Patients with a prior malignancy treated with curative intention are eligible if all treatment of that malignancy was completed at least 5 years before registration and the patient has no evidence of disease at registration. Less than 5 years is acceptable for malignancies with low risk of recurrence and/or no late recurrence. Patients with a germ cell neoplasia in situ (GCNIS) or contralateral localized treated seminoma are eligible
- Diagnostic CT or MRI or FDG-PET-CT of the chest, abdomen and pelvis within 28 days prior to registration, showing stage IIA/B disease. I.v. contrast medium has to be administered
- Age ≥ 18 years
- WHO performance status 0-2
- Baseline PRO questionnaires have been completed
- Adequate bone marrow function: neutrophil count ≥ 1.0 x 109/L, platelet count ≥ 100x 109/L
- Adequate renal function: creatinine clearance ≥ 60 ml/min calculated according to the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula
- Patient agrees to use highly effective contraception and not to donate sperm or to father a child during trial treatment and during 12 months thereafter. Patient has been proposed sperm conservation.
Exclusion criteria
- Any other histological component than seminoma
- Elevated levels of Alpha-1-Fetoprotein AFP (≥ 2x ULN)
- Involved nodes (metastatic) in previously irradiated localizations in the abdomen or pelvis
- Any anti-cancer therapy after primary tumor resection in patients presenting with primary stage IIA/B seminoma
- Any serious underlying medical condition (i.e. current renal insufficiency, severe hepatic insufficiency, severe bone marrow dysfunction, tumor bleeding, major hearing defects) or serious co-morbidity which could impair the ability of the patient to participate in the trial (according to investigator's judgment)
- Any treatment in a clinical trial within 28 days prior to registration
- Any concomitant drugs contraindicated for use with the trial drugs according to the approved product information or contraindicated for use with radiotherapy
- Known hypersensitivity to trial drugs or to any component of the trial drugs
- Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.
Additional German specific exclusion criteria - not to be considered for Swiss patients
- Patient who is dependent on the sponsor or the investigators according to ICH/GCP E6(R2), guideline
- Patient who has been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities according to § 40a (2) AMG.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm with 2 cohorts
Cohort 1: Primary stage IIA and recurrent stage IIA seminoma after active surveillance for stage I:
Cohort 2: Primary stage IIB and recurrent stage IIB seminoma after active surveillance for stage I OR stage IIA/B seminoma after adjuvant carboplatin or radiotherapy for stage I:
|
Patients in cohort 1 will receive a 60-minute i.v.
infusion of carboplatin AUC 7 at day 1 of treatment.
Patients in cohort 2 will receive on day 1 to day 5:
Patients in cohort 2 will receive on day 1 to day 5:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS) at 3 years
Time Frame: From the date of registration until the date of progressive disease, relapse or death, whichever occurs first, assessed up to 3 years after registration
|
PFS is defined as the time from registration until one of the following events occurs:
|
From the date of registration until the date of progressive disease, relapse or death, whichever occurs first, assessed up to 3 years after registration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate (RR)
Time Frame: at 3 months and 3 years after registration
|
The response is categorized according to the modified trial-specific version of RECIST 1.1 measurability criteria as: complete remission (CR), partial remission (PR), stable disease (SD), progressive disease (PD). The response rate is defined as proportion of patients with CR or PR on imaging assessment and without rising beta-hCG. Patients with CR, PR and SD on imaging assessment, but with confirmed rising beta-hCG will not be counted as responders, if the presence on non-seminoma germ cell tumor was excluded. Response rate will be evaluated at 3 months and 3 years after registration. |
at 3 months and 3 years after registration
|
Progression free survival (PFS)
Time Frame: From the date of registration until the date of progressive disease, relapse or death, whichever occurs first, assessed up to 20 years after registration
|
From the date of registration until the date of progressive disease, relapse or death, whichever occurs first, assessed up to 20 years after registration
|
|
Time to progression (TTP)
Time Frame: From the date of registration until the date of progressive disease, relapse or death due to progression, whichever occurs first, assessed up to 20 years after registration
|
TTP is defined as the time from registration until documented PD or relapse according to the modified trial-specific version of RECIST 1.1 or death due to progression, whichever occurs first. Patients without an event at the time of analysis and patients starting a new anticancer therapy in the absence of an event will be censored at the date of the last tumor assessment showing non-progression before the start of a new therapy, if any. |
From the date of registration until the date of progressive disease, relapse or death due to progression, whichever occurs first, assessed up to 20 years after registration
|
Overall Survival (OS)
Time Frame: From the date of registration until the date of death from any cause, assessed up to 20 years after registration
|
OS is defined as the time from registration to the date of death from any cause.
Patients who did not experience an event will be censored at the last known time they were known to be alive.
|
From the date of registration until the date of death from any cause, assessed up to 20 years after registration
|
Seminoma-specific survival
Time Frame: From the date of registration until the date of death due to seminoma, assessed up to 20 years after registration
|
Seminoma-specific survival is defined as the time from registration to the date of death due to seminoma.
Patients who did not experience an event will be censored at the last known time they were known to be alive.
|
From the date of registration until the date of death due to seminoma, assessed up to 20 years after registration
|
Time to distant metastasis
Time Frame: From the date of registration until the date of first occurrence of distant metastasis, assessed up to 20 years after registration
|
Time to distant metastasis is defined as the time from registration until first occurrence of distant metastasis.
Patients not experiencing an event will be censored at the date of the last available assessment.
|
From the date of registration until the date of first occurrence of distant metastasis, assessed up to 20 years after registration
|
Time to next treatment
Time Frame: From the date of registration until the date of start of any new anticancer therapy for progressive seminoma, assessed up to 20 years after registration
|
Time to next treatment is defined as the time from registration to the start of any new anticancer therapy for progressive seminoma.
Patients not receiving any new treatment are censored at the last date they were known to be alive.
|
From the date of registration until the date of start of any new anticancer therapy for progressive seminoma, assessed up to 20 years after registration
|
Localization of progression
Time Frame: at the date of the first occurrence of progressive disease, assessed from registration up to 20 years after registration
|
The localization of progression is defined as the first localization where progressive disease is detected. It is divided into the following sites:
|
at the date of the first occurrence of progressive disease, assessed from registration up to 20 years after registration
|
Method of detection of progression
Time Frame: at the date of the first occurrence of progressive disease, assessed from registration up to 20 years after registration
|
The method of detection of progression is defined as the first method used to detect the first progression event and comprises the following categories:
|
at the date of the first occurrence of progressive disease, assessed from registration up to 20 years after registration
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Alexandros Papachristofilou, MD, Universitätsspital Basel
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Genital Neoplasms, Male
- Testicular Diseases
- Neoplasms, Germ Cell and Embryonal
- Germinoma
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Testicular Neoplasms
- Seminoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Carboplatin
- Etoposide
Other Study ID Numbers
- SAKK 01/18
- 2019-000514-11 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seminoma
-
University of Southern CaliforniaNational Cancer Institute (NCI)Active, not recruitingLymphadenopathy | Stage I Testicular Seminoma | Stage II Testicular SeminomaUnited States
-
University Health Network, TorontoRecruitingStage II Testicular Seminoma | Lymphadenopathy RetroperitonealCanada
-
Barts & The London NHS TrustUniversity College London HospitalsCompletedMetastatic SeminomaUnited Kingdom
-
Abramson Cancer Center of the University of PennsylvaniaMassachusetts General HospitalCompleted
-
Tata Memorial CentreNot yet recruiting
-
Gustave Roussy, Cancer Campus, Grand ParisRecruiting
-
Swiss Group for Clinical Cancer ResearchActive, not recruiting
-
Heinrich-Heine University, DuesseldorfRecruiting
-
Centre Leon BerardRecruiting
-
Daiichi Sankyo, Inc.TerminatedNon-CNS Germ Cell Tumors (Seminomas and Nonseminomas)United States, France, United Kingdom
Clinical Trials on Carboplatin
-
Eisai Inc.CompletedCancerUnited States, Austria, India
-
Samyang Biopharmaceuticals CorporationCompleted
-
NHS Greater Glasgow and ClydeCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited Kingdom, Australia, New Zealand
-
Duke UniversityCompletedBrain and Central Nervous System TumorsUnited States, Canada
-
National Cancer Institute (NCI)Children's Oncology GroupCompletedBrain and Central Nervous System TumorsUnited States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ovarian CancerUnited States
-
AkesoRecruitingAdvanced Squamous Non Small Cell Lung CancerChina
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Eli Lilly and CompanyCompletedLung NeoplasmsUnited States